Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.5B
Close$
$88.82
37.4% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
37.4% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$133.10105.8% upside
Current Fair Value
105.8% upsideUndervalued by 105.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.50 Billion |
|---|---|
| Enterprise Value | $15.83 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.82 |
| Beta | 0.23 |
| Outstanding Shares | 192,959,000 |
Return
| Return on Equity | 1.15% |
|---|---|
| Return on Assets | 0.62% |
| Return on Invested Capital | 0.76% |
Valuation & Multiples
| P/E Ratio | 170.17 |
|---|---|
| PEG | -209.08 |
| Price to Sales | 3.8 |
| Price to Book Ratio | 2.02 |
| Enterprise Value to Revenue | 4.65 |
| Enterprise Value to EBIT | 207.66 |
| Enterprise Value to Net Income | 216 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 0.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.95
Average shareholder expectationRevenue Estimate
$932.03 M
Average shareholder expectationNext Earnings Call
Expected Date
October 26, 2026
EPS Estimate
$1.38
Average shareholder expectationRevenue Estimate
$1.03 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3698▼ 36.76% |
|---|---|
| Total Calls | 1,761,596▲ 18.21% |
| Total Puts | 651,500▼ 40.71% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.56%▲ 12.14% |
|---|---|
| Total Invested | $11.38B▲ 9.74% |
| Investors Holding | 586▲ 1.00% |
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime